NovaBay Pharmaceuticals I... (NBY)
Company Description
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally.
It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands.
The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand.
It sells its products through retailers, digital beauty channels, and distributors, as well as online.
The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007.
NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Country | United States |
IPO Date | Oct 26, 2007 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 13 |
CEO | Justin M. Hall Esq., J.D. |
Contact Details
Address: 2000 Powell Street EmeryVille, California United States | |
Website | https://novabay.com |
Stock Details
Ticker Symbol | NBY |
Exchange | AMEX |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001389545 |
CUSIP Number | 66987P201 |
ISIN Number | US66987P3001 |
Employer ID | 68-0454536 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Justin M. Hall Esq., J.D. | President, Chief Executive Officer, General Counsel, Chief Compliance Officer, Corporate Secretary & Director |
Tommy Law | Controller, Interim Chief Financial Officer & Treasurer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 22, 2025 | 8-K | Current Report |
Apr 15, 2025 | 4 | Filing |
Apr 15, 2025 | 4 | Filing |
Apr 15, 2025 | 4 | Filing |
Apr 15, 2025 | 4 | Filing |
Apr 15, 2025 | 4 | Filing |
Apr 15, 2025 | 4 | Filing |
Apr 15, 2025 | 4 | Filing |
Apr 07, 2025 | 3 | Filing |
Apr 02, 2025 | 10-K | Annual Report |